TY - JOUR
T1 - The effect of anti-seizure medications on lipid values in adults with epilepsy
AU - Muller, Ashley L.
AU - Diaz-Arias, Luisa
AU - Cervenka, Mackenzie C.
AU - McDonald, Tanya J.W.
N1 - Funding Information:
This study was funded by generous philanthropic support from The Johns Hopkins Center for Refractory Status Epilepticus and Neuroinflammation, and the Johns Hopkins KL2 Mentored Career Development Award (1 KL2 TR 3099-1). Study sponsors played no role in the study design, collection, analysis, or interpretation of data. Study sponsors also played no role in the writing of the report and in the decision to submit the article for publication.
Funding Information:
The authors would like to acknowledge patients who participated in the study, Johns Hopkins Adult Epilepsy Diet Center Medical Office Coordinators Joanne Barnett and Corri Woodland, and nurse Rebecca Fisher.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/7
Y1 - 2023/7
N2 - Purpose: Certain anti-seizure medications (ASMs) adversely impact lipid values. Here, we explored the impact of ASMs on lipid values in adults with epilepsy. Methods: A total of 228 adults with epilepsy were divided into four groups based on ASMs used: strong EIASMs, weak EIASMs, non-EIASMs, and no ASMs. Demographic information, epilepsy-specific clinical history, and lipid values were obtained through chart review. Results: While there was no significant difference in lipid values between groups, there was a significant difference in the proportion of participants with dyslipidemia. Specifically, more participants exhibited elevated low-density lipoprotein (LDL) level in the strong EIASM group compared to the non-EIASM group (46.7% vs 18%, p < 0.05). In addition, more participants showed elevated LDL level in the weak EIASM group compared to the non-EIASM group (38% vs 18%, p < 0.05). Users of strong EIASMs showed greater odds of high LDL level (OR 5.734, p = 0.005) and high total cholesterol level (OR 4.913, p = 0.008) compared to users of non-EIASMs. When we analyzed the impact of individual ASMs used by more than 15% of the cohort on lipid levels, participants using valproic acid (VPA) showed lower high-density lipoprotein (p = 0.002) and higher triglyceride levels (p = 0.002) compared to participants not using VPA. Conclusion: Our study demonstrated a difference in the proportion of participants with dyslipidemia between ASM groups. Thus, adults with epilepsy using EIASMs should have careful monitoring of lipid values to address the risk of cardiovascular disease.
AB - Purpose: Certain anti-seizure medications (ASMs) adversely impact lipid values. Here, we explored the impact of ASMs on lipid values in adults with epilepsy. Methods: A total of 228 adults with epilepsy were divided into four groups based on ASMs used: strong EIASMs, weak EIASMs, non-EIASMs, and no ASMs. Demographic information, epilepsy-specific clinical history, and lipid values were obtained through chart review. Results: While there was no significant difference in lipid values between groups, there was a significant difference in the proportion of participants with dyslipidemia. Specifically, more participants exhibited elevated low-density lipoprotein (LDL) level in the strong EIASM group compared to the non-EIASM group (46.7% vs 18%, p < 0.05). In addition, more participants showed elevated LDL level in the weak EIASM group compared to the non-EIASM group (38% vs 18%, p < 0.05). Users of strong EIASMs showed greater odds of high LDL level (OR 5.734, p = 0.005) and high total cholesterol level (OR 4.913, p = 0.008) compared to users of non-EIASMs. When we analyzed the impact of individual ASMs used by more than 15% of the cohort on lipid levels, participants using valproic acid (VPA) showed lower high-density lipoprotein (p = 0.002) and higher triglyceride levels (p = 0.002) compared to participants not using VPA. Conclusion: Our study demonstrated a difference in the proportion of participants with dyslipidemia between ASM groups. Thus, adults with epilepsy using EIASMs should have careful monitoring of lipid values to address the risk of cardiovascular disease.
KW - Cholesterol
KW - Ketogenic Diet
KW - Modified Atkins Diet
KW - Seizures
UR - http://www.scopus.com/inward/record.url?scp=85159915888&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159915888&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2023.109260
DO - 10.1016/j.yebeh.2023.109260
M3 - Article
C2 - 37244221
AN - SCOPUS:85159915888
SN - 1525-5050
VL - 144
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
M1 - 109260
ER -